Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A girl with brownish grey macules on and around the lips].

Nederlands tijdschrift voor geneeskunde·2021
Same author

CXCL10/IP-10, an early biomarker for late sequelae in DRESS?

The British journal of dermatology·2020
Same author

Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.

Diabetes & metabolism·2019
Same author

Randomized clinical trial of endovenous laser ablation versus direct and indirect radiofrequency ablation for the treatment of great saphenous varicose veins.

The British journal of surgery·2019
Same author

T-cell responses against 4-tert-butylphenol-exposed pigmented cells in a patient with occupational vitiligo.

The British journal of dermatology·2019
Same author

The impact of laboratory closing times on delay of adequate therapy in blood stream infections.

The Netherlands journal of medicine·2018
Same journal

Real-World Outcomes of Stapokibart-Based Combination Therapy for Bullous Pemphigoid: A Single-Center Retrospective Cohort.

Clinical and experimental dermatology·2026
Same journal

A second case of recessive mosaicism in ABCA12 causing a congenital unilateral epidermal nevus.

Clinical and experimental dermatology·2026
Same journal

Dermatopathology.

Clinical and experimental dermatology·2026
Same journal

Persistent Bilateral Palmar Hyperkeratotic Papules in an Adolescent Male.

Clinical and experimental dermatology·2026
Same journal

Shuddering Attacks in an Infant Treated with Atenolol for Infantile Hemangioma: A Previously Unreported Adverse Effect.

Clinical and experimental dermatology·2026
Same journal

Male genital fixed drug eruption: a systematic review.

Clinical and experimental dermatology·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Imatinib-induced pseudoporphyria.

L Timmer-de Mik1, S H Kardaun, M H H Kramer

  • 1Departments of Dermatology, Meander Medical Center, Amersfoort, The Netherlands.

Clinical and Experimental Dermatology
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Imatinib, a tyrosine kinase inhibitor, can cause pseudoporphyria, a rare skin condition. Physicians should monitor for this adverse effect and advise patients on photoprotection.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Experiment Videos

Last Updated: Jun 27, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Area of Science:

  • Oncology
  • Dermatology

Background:

  • Imatinib is a key tyrosine kinase inhibitor for chronic myeloid leukemia.
  • Adverse effects of imatinib are common, often mild, and typically transient.
  • Cutaneous reactions are frequently observed during imatinib therapy.

Observation:

  • Pseudoporphyria is a known side effect of various medications, including NSAIDs.
  • This report details a case of pseudoporphyria induced by imatinib therapy.
  • The expanding list of causative agents for pseudoporphyria includes imatinib.

Findings:

  • Imatinib can induce pseudoporphyria, a blistering skin condition.
  • This adverse reaction may manifest during imatinib treatment for chronic myeloid leukemia.

Implications:

  • Increased awareness of imatinib-induced pseudoporphyria is crucial for clinicians.
  • Early recognition and management, including photoprotection, can enhance patient compliance.
  • This finding highlights the importance of monitoring for dermatological side effects in patients on imatinib.